Last 12 months
Inside the activity.
0 purchase rows · 8 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2023 Filed Dec 14, 2023 21:05 UTC |
Zelnick Kaufman BethChief Legal Officer
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000929638-23-003428 · form4.xml · nonDerivative · entry 1 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · price: These Restricted Stock Units were granted on 12/12/2023. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 21:00 UTC |
Mistry ErinChief Commercial Officer
|
PurchaseCommon Stock | 1,000 | $4.00 | $4,000.00 |
DisclosureSEC source: 0000929638-23-003205 · form4.xml · nonDerivative · entry 1 Mistry Erin · CIK 0001962774 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,900 Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 21:50 UTC |
Lefkowitz Steven WDirector
|
Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 15,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0000929638-23-003170 · form4.xml · derivative · entry 4 Lefkowitz Steven W · CIK 0001313149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These stock options, representing a right to purchase 15,000 shares of Common Stock, were granted on June 25, 2017. These stock options are fully vested. Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 21:50 UTC |
Lefkowitz Steven WDirector
|
Exercise / conversionCommon Stock | 15,000 | $2.25 | $33,750.00 |
DisclosureSEC source: 0000929638-23-003170 · form4.xml · nonDerivative · entry 1 Lefkowitz Steven W · CIK 0001313149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2023 Filed Sep 8, 2023 20:21 UTC |
Todisco JosephDirector · Chief Executive Officer
|
PurchaseCommon Stock | 10,000 | $3.71 | $37,100.00 |
DisclosureSEC source: 0000929638-23-002490 · form4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,726 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.7099 to $3.71, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 18, 2023 Filed May 19, 2023 16:02 UTC |
Kaplan MyronDirector
|
PurchaseCommon Stock | 6,000 | $4.54 | $27,258.00 |
DisclosureSEC source: 0000929638-23-001538 · form4.xml · nonDerivative · entry 1 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,034 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.53 to $4.55, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 17, 2023 Filed May 17, 2023 17:37 UTC |
Stewart Robert ADirector
|
GrantCommon Stock | 10,000 | $4.37 | $43,735.00 |
DisclosureSEC source: 0000929638-23-001519 · form4.xml · nonDerivative · entry 1 Stewart Robert A · CIK 0001476493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Read SEC document |
| May 17, 2023 Filed May 17, 2023 19:25 UTC |
Costa Paulo FDirector
|
GrantCommon Stock | 10,000 | $4.65 | $46,500.00 |
DisclosureSEC source: 0000929638-23-001521 · form4.xml · nonDerivative · entry 1 Costa Paulo F · CIK 0001465928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.605 to $4.65, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 17, 2023 Filed May 17, 2023 23:08 UTC |
DUNTON ALAN WDirector
|
GrantCommon Stock | 3,000 | $4.33 | $12,979.80 |
DisclosureSEC source: 0000929638-23-001520 · form4.xml · nonDerivative · entry 1 DUNTON ALAN W · CIK 0001304773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,250 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.31 to $4.34, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 17, 2023 Filed May 17, 2023 21:35 UTC |
Todisco JosephDirector · Chief Executive Officer
|
GrantCommon Stock | 5,000 | $4.58 | $22,900.00 |
DisclosureSEC source: 0000929638-23-001517 · form4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,726 Read SEC document |
| May 17, 2023 Filed May 18, 2023 16:51 UTC Amendment |
Stewart Robert ADirector
|
PurchaseCommon Stock | 10,000 | $4.37 | $43,735.00 |
DisclosureSEC source: 0000929638-23-001529 · form4.xml · nonDerivative · entry 1 Stewart Robert A · CIK 0001476493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 F1 · kind: On May 17, 2023, the reporting person filed a Form 4 which inadvertently included Transaction Code "A". The original Form 4 should have indicated Transaction Code "P". The reporting person has filed this amendment to restate the transaction with the correct Transaction Code. Read SEC document |
| May 17, 2023 Filed May 18, 2023 18:26 UTC Amendment |
Costa Paulo FDirector
|
PurchaseCommon Stock | 10,000 | $4.65 | $46,500.00 |
DisclosureSEC source: 0000929638-23-001532 · form4.xml · nonDerivative · entry 1 Costa Paulo F · CIK 0001465928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · kind: On May 17, 2023, the reporting person filed a Form 4 which inadvertently included Transaction Code "A". The original Form 4 should have indicated Transaction Code "P". The reporting person has filed this amendment to restate the transaction with the correct Transaction Code. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.605 to $4.65, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 17, 2023 Filed May 18, 2023 20:49 UTC Amendment |
Todisco JosephDirector · Chief Executive Officer
|
PurchaseCommon Stock | 5,000 | $4.58 | $22,900.00 |
DisclosureSEC source: 0000929638-23-001527 · form4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,726 F1 · kind: On May 17, 2023, the reporting person filed a Form 4 which inadvertently included Transaction Code "A". The original Form 4 should have indicated Transaction Code "P". The reporting person has filed this amendment to restate the transaction with the correct Transaction Code. Read SEC document |
| May 17, 2023 Filed May 18, 2023 21:05 UTC Amendment |
DUNTON ALAN WDirector
|
PurchaseCommon Stock | 3,000 | $4.33 | $12,979.80 |
DisclosureSEC source: 0000929638-23-001531 · form4.xml · nonDerivative · entry 1 DUNTON ALAN W · CIK 0001304773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,250 F1 · kind: On May 17, 2023, the reporting person filed a Form 4 which inadvertently included Transaction Code "A". The original Form 4 should have indicated Transaction Code "P". The reporting person has filed this amendment to restate the transaction with the correct Transaction Code. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.31 to $4.34, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 10, 2023 Filed May 12, 2023 22:16 UTC |
Todisco JosephDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 37,443 | $5.30 | $198,447.90 |
DisclosureSEC source: 0000929638-23-001441 · form4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,726 Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 16:06 UTC |
Stewart Robert ADirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 14,200 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0000929638-23-001181 · form4.xml · derivative · entry 2 Stewart Robert A · CIK 0001476493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,200 Underlying: Common Stock · 14,200 shares Expires 2033-04-13 F2 · derivative.exercise_date: These options were granted on 04/13/2023 and are subject to monthly vesting in equal installments during the one-year period beginning on 05/23/2023, subject to continued service on the board of directors. Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 16:06 UTC |
Stewart Robert ADirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 25,000 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0000929638-23-001181 · form4.xml · derivative · entry 1 Stewart Robert A · CIK 0001476493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-04-13 F1 · derivative.exercise_date: These options were granted on 04/13/2023. One-third of the options vested on the date of grant. One-third of the options will vest on each of the first and second anniversaries of the grant, subject to continued service on the board of directors. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 18:53 UTC |
David Matthew TChief Financial Officer
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 125,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001213900-23-003547 · ownership.xml · derivative · entry 2 David Matthew T · CIK 0001811612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-01-14 F1 · derivative.exercise_date: These options were granted on 1/14/2023. These options vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 19:04 UTC |
Mounts PhoebeGeneral Counsel
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 125,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001213900-23-003556 · ownership.xml · derivative · entry 2 Mounts Phoebe · CIK 0001777330 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-01-14 F1 · derivative.exercise_date: These options were granted on 1/14/2023. These options vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 19:00 UTC |
Kaplan MyronDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001213900-23-003553 · ownership.xml · derivative · entry 4 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-01-14 F2 · derivative.exercise_date: These options were granted on 1/14/2023. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 19:01 UTC |
Dillione JanetDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001213900-23-003554 · ownership.xml · derivative · entry 2 Dillione Janet · CIK 0001489798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-01-14 F1 · derivative.exercise_date: These options were granted on 1/14/2023. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 18:51 UTC |
Costa Paulo FDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001213900-23-003546 · ownership.xml · derivative · entry 1 Costa Paulo F · CIK 0001465928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-01-14 F1 · derivative.exercise_date: These options were granted on 1/14/2023. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 14, 2023 Filed Jan 19, 2023 00:04 UTC |
Todisco JosephDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 400,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001213900-23-003557 · ownership.xml · derivative · entry 2 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-01-14 F1 · derivative.exercise_date: These options were granted on 1/14/2023. These options vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| January 14, 2023 Filed Jan 19, 2023 00:02 UTC |
Lefkowitz Steven WDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001213900-23-003555 · ownership.xml · derivative · entry 4 Lefkowitz Steven W · CIK 0001313149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-01-14 F2 · derivative.exercise_date: These options were granted on 1/14/2023. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 14, 2023 Filed Jan 19, 2023 00:00 UTC |
Hurlburt ElizabethEVP, Head of Clinical Ops.
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 125,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001213900-23-003552 · ownership.xml · derivative · entry 2 Masson-Hurlburt Elizabeth · CIK 0001735256 · EVP, Head of Clinical Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-01-14 F1 · derivative.exercise_date: These options were granted on 1/14/2023. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 23:59 UTC |
DUNTON ALAN WDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001213900-23-003550 · ownership.xml · derivative · entry 2 DUNTON ALAN W · CIK 0001304773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-01-14 F1 · derivative.exercise_date: These options were granted on 1/14/2023. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 23:56 UTC |
Duncan Gregory ScottDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001213900-23-003549 · ownership.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-01-14 F1 · derivative.exercise_date: These options were granted on 1/14/2023. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 14, 2023 Filed Jan 20, 2023 23:05 UTC |
Mistry ErinChief Commercial Officer
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 75,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001567619-23-001095 · doc1.xml · derivative · entry 2 Mistry Erin · CIK 0001962774 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-14 F1 · derivative.exercise_date: These options were granted on 1/14/2023. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:56 UTC |
Todisco JosephDirector · Chief Executive Officer
|
PurchaseCommon Stock | 20,000 | $3.82 | $76,400.00 |
DisclosureSEC source: 0001213900-22-073225 · ownership.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,169 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.77 to $3.85, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| August 24, 2022 Filed Aug 25, 2022 12:37 UTC |
Todisco JosephDirector · Chief Executive Officer
|
PurchaseCommon Stock | 4,700 | $3.92 | $18,424.00 |
DisclosureSEC source: 0001213900-22-050936 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,169 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.91 to $3.92, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 17, 2022 Filed May 18, 2022 17:21 UTC |
Kaplan MyronDirector
|
PurchaseCommon Stock | 5,000 | $3.78 | $18,900.00 |
DisclosureSEC source: 0001213900-22-027983 · ownership.xml · nonDerivative · entry 1 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,034 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.77 to $3.79, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 16, 2022 Filed May 17, 2022 12:30 UTC |
Todisco JosephDirector · Chief Executive Officer
|
PurchaseCommon Stock | 10,000 | $3.38 | $33,800.00 |
DisclosureSEC source: 0001213900-22-027450 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,469 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.36 to $3.40, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 10, 2022 Filed May 12, 2022 20:30 UTC |
Todisco JosephDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 500,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001213900-22-025973 · doc4.xml · derivative · entry 2 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2032-05-09 F2 · derivative.exercise_date: These options were granted on 5/10/2022. These options vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date. Read SEC document |
| May 10, 2022 Filed May 12, 2022 20:30 UTC |
Todisco JosephDirector · Chief Executive Officer
|
GrantCommon Stock | 207,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-025973 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,469 F1 · price: These Restricted Stock Units were granted on 5/10/2022. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vest as follows: 50% on the first anniversary of the grant date, 30% on the second anniversary of the grant date, and the remaining 20% on the third anniversary of the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 16:16 UTC |
Kaplan MyronDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001213900-22-008949 · doc4.xml · derivative · entry 2 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-22 F7 · derivative.exercise_date: These options were granted on 2/22/2022. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 17:43 UTC |
Dillione JanetDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0000929638-22-000532 · form4.xml · derivative · entry 2 Dillione Janet · CIK 0001489798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-22 F9 · derivative.exercise_date: These options were granted on 2/22/2022. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 16:29 UTC |
Costa Paulo FDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001213900-22-008970 · doc4.xml · derivative · entry 1 Costa Paulo F · CIK 0001465928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2022-02-22 F4 · derivative.exercise_date: These options were granted on 2/22/2022. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:23 UTC |
Duncan Gregory ScottDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001213900-22-008962 · doc4.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-22 F4 · derivative.exercise_date: These options were granted on 2/22/2022. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:20 UTC |
DUNTON ALAN WDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001213900-22-008959 · doc4.xml · derivative · entry 2 DUNTON ALAN W · CIK 0001304773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-22 F5 · derivative.exercise_date: These options were granted on 2/22/2022. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:18 UTC |
Lefkowitz Steven WDirector
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001213900-22-008953 · doc4.xml · derivative · entry 4 Lefkowitz Steven W · CIK 0001313149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-22 F7 · derivative.exercise_date: These options were granted on 2/22/2022. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 16:14 UTC |
Nusbickel ThomasEVP, Chief Commercial Officer
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 100,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001213900-22-008943 · doc4.xml · derivative · entry 1 Nusbickel Thomas · CIK 0001863281 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-18 F1 · derivative.exercise_date: These options were granted on 02/18/2022. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 16:09 UTC |
David Matthew TInterim CEO and CFO
|
GrantStock Option (Right to Buy Common Stock) · Derivative | Not disclosed | $0.00 Strike: $4.03 | $100,000.00 |
DisclosureSEC source: 0001213900-22-008933 · doc4.xml · derivative · entry 2 David Matthew T · CIK 0001811612 · Interim CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-18 F4 · derivative.exercise_date: These options were granted on 2/18/2022. These options vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 16:10 UTC |
Mounts PhoebeGeneral Counsel
|
GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001213900-22-008936 · doc4.xml · derivative · entry 2 Mounts Phoebe · CIK 0001777330 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2032-02-18 F6 · derivative.exercise_date: These options were granted on 2/18/2022. These options vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:12 UTC |
Hurlburt ElizabethEVP, Head of Clinical Ops.
|
GrantStock Option (Right to Buy Common Stock) · Derivative | 100,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001213900-22-008940 · doc4.xml · derivative · entry 2 Masson-Hurlburt Elizabeth · CIK 0001735256 · EVP, Head of Clinical Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-18 F6 · derivative.exercise_date: These options were granted on 02/18/2022. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 16:08 UTC |
Kaplan MyronDirector
|
GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-067924 · doc4.xml · nonDerivative · entry 4 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,034 F7 · kind: The reporting person gifted these shares of common stock to his family members. The reporting person is not deemed to be the beneficial owner of these shares. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 16:08 UTC |
Kaplan MyronDirector
|
GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-067924 · doc4.xml · nonDerivative · entry 3 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,034 F7 · kind: The reporting person gifted these shares of common stock to his family members. The reporting person is not deemed to be the beneficial owner of these shares. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 16:08 UTC |
Kaplan MyronDirector
|
GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-067924 · doc4.xml · nonDerivative · entry 2 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,034 F7 · kind: The reporting person gifted these shares of common stock to his family members. The reporting person is not deemed to be the beneficial owner of these shares. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 16:08 UTC |
Kaplan MyronDirector
|
GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-067924 · doc4.xml · nonDerivative · entry 1 Kaplan Myron · CIK 0001672645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,034 F7 · kind: The reporting person gifted these shares of common stock to his family members. The reporting person is not deemed to be the beneficial owner of these shares. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 18:44 UTC |
David Matthew TInterim CEO and CFO
|
PurchaseCommon Stock | 1,000 | $4.50 | $4,500.00 |
DisclosureSEC source: 0001213900-21-064007 · doc4.xml · nonDerivative · entry 1 David Matthew T · CIK 0001811612 · Interim CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,150 Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 18:44 UTC |
David Matthew TInterim CEO and CFO
|
PurchaseCommon Stock | 1,000 | $4.50 | $4,500.00 |
DisclosureSEC source: 0001213900-21-064006 · doc4.xml · nonDerivative · entry 1 David Matthew T · CIK 0001811612 · Interim CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,150 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.